Ref (type)	Population	Outcome, Interventions	Results and statistical analysis	Effect size	Favours
Adverse effects (any)
Systematic review	1148 people 6 RCTs in this analysis	Proportion of people withdrawing from RCT 151/571 (26%) with sertraline 138/577 (24%) with placebo	RR 1.10 95% CI 0.90 to 1.33		Not significant
RCT	208 people In review	Proportion of people with insomnia 35% with sertraline 22% with placebo Absolute numbers not reported	P = 0.04	Effect size not calculated	placebo
RCT	208 people In review	Proportion of people with diarrhoea 28% with sertraline 11% with placebo Absolute numbers not reported	P = 0.003	Effect size not calculated	placebo
RCT	208 people In review	Proportion of people with nausea 23% with sertraline 11% with placebo Absolute numbers not reported	P = 0.03	Effect size not calculated	placebo
RCT	208 people In review	Proportion of people with decreased appetite 12% with sertraline 1% with placebo Absolute numbers not reported	P = 0.001	Effect size not calculated	placebo
RCT	169 people with combat-related PTSD	Proportion of people with fatigue 12 weeks 9/86 (11%) with sertraline (25–200 mg/day, flexible dose) 1/83 (1%) with placebo	P = 0.018	Effect size not calculated	placebo
RCT	169 people with combat-related PTSD	Proportion of people discontinuing treatment 12 weeks 26/86 (30%) with sertraline (25–200 mg/day, flexible dose) 14/83 (17%) with placebo	P = 0.041	Effect size not calculated	placebo
RCT	169 people with combat-related PTSD	Proportion of people with diarrhoea 12 weeks 27/86 (31%) with sertraline (25–200 mg/day, flexible dose) 15/83 (18%) with placebo	Reported as not significant P value not reported		Not significant
RCT	169 people with combat-related PTSD	Proportion of people with headache 12 weeks 23/86 (27%) with sertraline (25–200 mg/day, flexible dose) 20/83 (24%) with placebo	Reported as not significant P value not reported		Not significant
RCT	169 people with combat-related PTSD	Proportion of people with insomnia 12 weeks 12/86 (14%) with sertraline (25–200 mg/day, flexible dose) 8/83 (10%) with placebo	Reported as not significant P value not reported		Not significant